ENLIVEN THERAPEUTICS INC
ELVN · NASDAQ
Updated at 2026-10-14 08:35:07
- Today's High
- $40.99
- Today’s Low
- $39.27
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $40.67
- Previous Close
- $40.84
- Volume
- 579.82K
- Market Cap
- $2.99B
- P/E Ratio
- --
- EPS
- $-1.66
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 6200 LOOKOUT ROAD, BOULDER, CO, UNITED STATES, 80301
- Country
- US
- Listing Date
- 2020-03-12
- Fiscal Year End
- December
- Shares Outstanding
- 69.82M
- CIK
- 0001672619
- Website
- www.enliventherapeutics.com
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its proprietary therapeutic platforms. With a robust pipeline of advanced drug candidates developed using cutting-edge biopharmaceutical technologies, the company is dedicated to enhancing patient care and quality of life. Enliven's commitment to scientific excellence and its mission to fulfill unmet needs in oncology strategically position it for substantial shareholder value while making a meaningful contribution to the healthcare ecosystem.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$37.2M
2026-03-31
$27.82M
2025-12-31
$34.23M
2025-09-30
$25.09M
Net Income
2026-06-30
-$32.48M
2026-03-31
-$23.62M
2025-12-31
-$29.66M
2025-09-30
-$20.14M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.49
2026-03-31
$-0.38
2025-12-31
$-0.48
2025-09-30
$-0.32
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$32.47M
2026-03-31
-$23.61M
2025-12-31
-$29.62M
2025-09-30
-$20.08M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $37.2M | $27.82M | $34.23M | $25.09M |
| Net Income | -$32.48M | -$23.62M | -$29.66M | -$20.14M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.49 | $-0.38 | $-0.48 | $-0.32 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$32.47M | -$23.61M | -$29.62M | -$20.08M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.